Wednesday, 7 December 2016

TherapeuticsMD shares jump 20% on menopause drug study results

TherapeuticsMD Inc. TXMD, +12.80% offers bounced in the broadened session Monday after the ladies' medication engineer said a late-arrange clinical trial demonstrated its medication competitor decreased vasomotor indications in ladies experiencing menopause. TherapeuticsMD offers surged 22% to $7.52 nightfall on substantial volume. Vasomotor side effects incorporate such events as night sweats, hot flashes, and flushes. The organization said its medication competitor TX-001HR essentially diminished the number and seriousness of these side effects in menopausal and post-menopausal ladies contrasted with those treated with a fake treatment.

Time (EST)

TherapeuticsMD Inc.

10:00

11:00

12:00

1:00

2:00

3:00

$6.4$6.6$6.8$7.0$7.2$7.4

No comments:

Post a Comment

Note: only a member of this blog may post a comment.